Jaques Buvat
Risk assessmentInternal medicineUrologyEndocrinologyEtiologyPsychologyRenal functionCardiologyRandomized controlled trialPediatricsMedical historyPlaceboSexual functionDelayed pubertyCombination therapySexual desireType 2 diabetesAcromegalyAndrogenSexual dysfunctionCoronary artery diseaseProlactinDiseaseTestosterone (patch)LibidoErectile dysfunctionHypergonadotropic hypogonadismPublication biasMetabolic syndromeEndothelial dysfunctionFamily historyGynecologyGonadotropin secretionCardiovascular mortalityErectile functionPhysiologyPharmacotherapyRisk factorFertilityPhysical examinationTestosteroneHormoneMedicinecGMP-specific phosphodiesterase type 5Bone ageMeta-analysis
8Publications
5H-index
377Citations
Publications 8
Newest
#1Giovanni CoronaH-Index: 84
#2Andrea M. Isidori (Sapienza University of Rome)H-Index: 64
Last. Mario Maggi (UniFI: University of Florence)H-Index: 160
view all 11 authors...
Introduction. The role of testosterone supplementation (TS) as a treatment for male sexual dysfunction remains questionable. Aim. The aim of this study was to attempt a meta-analysis on the effect of TS on male sexual function and its synergism with the use of phosphodiesterase type 5 inhibitor (PDE5i). Methods. An extensive Medline, Embase, and Cochrane search was performed. Main Outcome Measures. All randomized controlled trials (RCTs) comparing the effect of TS vs. placebo or the effect of TS...
168 CitationsSource
#1Giovanni CoronaH-Index: 84
#2Andrea M. IsidoriH-Index: 64
Last. Mario MaggiH-Index: 160
view all 9 authors...
Source
#1Graham Jackson (Guy's and St Thomas' NHS Foundation Trust)H-Index: 71
#1Graham Jackson (St Thomas' Hospital)H-Index: 29
Last. Frederick C. W. Wu (University of Manchester)H-Index: 84
view all 21 authors...
Erectile dysfunction (ED) and cardiovascular disease (CVD) share risk factors and frequently coexist, with endothelial dysfunction believed to be the pathophysiologic link. ED is common, affecting more than 70% of men with known CVD. In addition, clinical studies have demonstrated that ED in men with no known CVD often precedes a CVD event by 2-5 years. ED severity has been correlated with increasing plaque burden in patients with coronary artery disease. ED is an independent marker of increased...
42 CitationsSource
#1Mario Maggi (UniFI: University of Florence)H-Index: 160
#2Jaques BuvatH-Index: 5
Last. Luiz Otavio TorresH-Index: 16
view all 5 authors...
ABSTRACT Introduction Besides hypogonadism, other endocrine disorders have been associated with male sexual dysfunction (MSD). Aim To review the role of the pituitary hormone prolactin (PRL), growth hormone (GH), thyroid hormones, and adrenal androgens in MSD. Methods A systematic search of published evidence was performed using Medline (1969 to September 2011). Oxford Centre for Evidence‐Based Medicine—Levels of Evidence (March 2009) was applied when possible. Main Outcome Measures The most imp...
87 CitationsSource
#1Mario Maggi (UniFI: University of Florence)H-Index: 160
#2Jaques BuvatH-Index: 5
ABSTRACT Introduction Delayed puberty (DP) is a condition characterized by the lack of sexual maturation in boys (testis volume Aim To review the etiology, pathogenesis diagnosis, and the available treatments for DP in males. Methods A systematic search of published evidence was performed using Medline (1969 to September 2011). Main Outcome Measures The most important evidence regarding DP and the available treatment options were reviewed and discussed. Whenever possible, levels of evidence are ...
13 CitationsSource
#1Giulia RastrelliH-Index: 48
#2Giovanni CoronaH-Index: 84
Last. Mario MaggiH-Index: 160
view all 9 authors...
64 Citations
#1Giovanni CoronaH-Index: 84
#2Giulia RastrelliH-Index: 48
Last. Mario MaggiH-Index: 2
view all 8 authors...
#1Ridwan Shabsigh (Columbia University)H-Index: 59
#2J. Rajfer (UCLA Medical Center)H-Index: 1
Last. Jaques BuvatH-Index: 5
view all 7 authors...
Summary Hypogonadism may play a significant role in the pathophysiology of erectile dysfunction (ED). A threshold level of testosterone may be necessary for normal erectile function. Testosterone replacement therapy is indicated in hypogonadal patients and is beneficial in patients with ED and hypogonadism. Monotherapy with testosterone for ED is of limited effectiveness and may be most promising in young patients with hypogonadism and without vascular risk factors for ED. A number of laboratory...
95 CitationsSource